Tag:
Provenge
Latest Headlines
Latest Headlines
Cancer vaccine developers bask in Provenge limelight
Now that Dendreon has completed its victory lap following Thursday's high-profile approval for Provenge, the spotlight has inevitably shifted to the other cancer vaccines in the pipeline. "It sets
The Twitter newsroom is packed with biopharma writers
After I had just finished wrapping up my daily missive from FierceBiotech yesterday, a tweet caught my eye at the corner of the screen. @adamfeuerstein from TheStreet had just picked up the first
Dendreon: Provenge to cost $93K for full course of treatment
One of the most pressing questions analysts and patients have had about Provenge is how much Dendreon would charge for its newly approved prostate cancer drug. Following this afternoon's conference
FDA approves Dendreon's breakthrough cancer vaccine Provenge
The FDA has approved Dendreon's Provenge, a breakthrough cancer vaccine that promises to extend the lives of prostate cancer victims by several months. Widely seen as a likely blockbuster with a cost
Dendreon plays waiting game as Provenge deadline looms
Sometime by the end of tomorrow, the FDA should deliver its final decision on Dendreon's (NASDAQ: DNDN) Provenge, a potential breakthrough therapeutic cancer vaccine. (The official deadline is on
Biotech watchers on high alert for Provenge decision
Just about every biotech analyst on the planet knows that the FDA is facing a May 1 deadline for a decision on Dendreon's Provenge. As that's a Saturday, we're likely to hear about a final decision
How much is too much to pay for Provenge?
With Dendreon's hotly anticipated prostate cancer drug Provenge on the doorstep of FDA approval, the company now must answer a tough question: How much can they charge for a drug that extends
Researchers see cancer vaccine revolution on the horizon
There are already several cancer vaccine drugs nearing FDA approval. Dendreon's prostate cancer vaccine Provenge is awaiting the agency's OK, and Merck KGaA's Stimuvax is in trials for multiple
A blockbuster FDA deadline looms and Dendreon shares turn red-hot
With the FDA's deadline on a final decision regarding Dendreon's Provenge less than a month away, investors have made the Seattle-based biotech's stock one of this month's hottest plays. Earlier
Dendreon tripling workforce ahead of expected vax launch
Over the years Seattle-based Dendreon made a global name for itself as it developed one of the world's first therapeutic vaccines. It's also advanced the careers of scores of biotech executives who
